Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2033

Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.

Patents
1,330

Quick answer

1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8492407

    Quaternary ammonium compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Jul 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8492403

    Bicyclic derivatives as modulators of voltage gated ion channels

    Vertex Pharmaceuticals Incorporated · Granted Tue Jul 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8492405

    Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8497357

    Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom

    Nektar Therapeutics · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8497271

    Modulators of G protein-coupled receptor 88

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8497258

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    The Regents of the University of California · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8497274

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8497287

    Aminotetralin compounds as mu opioid receptor antagonists

    Theravance, Inc. · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8497290

    Thiocolchicine derivatives, method of making and methods of use thereof

    Takeda Pharmaceuticals U.S.A., Inc. · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8497381

    Antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8497301

    Hydroxyl compounds and compositions for cholesterol management and related uses

    Esperion Therapeutics, Inc. · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8497249

    Fungicidal properties of three saponins from Capsicum frutescens

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8497241

    WNT10-derived peptide and use thereof

    CAREGEN CO., LTD. · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8497307

    Aryl guanidine F1F0-ATPase inhibitors and related methods

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8496938

    Anti-CD100 neutralizing neutralizing antibodies and methods of using the same

    VACCINEX, INC. · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8497393

    Process to prepare treprostinil, the active ingredient in Remodulin®

    United Therapeutics Corporation · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8496957

    Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

    The Regents of the University of California · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8497279

    Treatment for discoid lupus

    Rigel Pharmaceuticals, Inc. · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8497295

    Spiroindoline modulators of muscarinic receptors

    Vertex Pharmaceuticals Incorporated · Granted Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. EP 2620148

    Antitumorkombination mit Cabazitaxel und Cisplatin

    AVENTIS PHARMA SA [FR] · Granted Wed Jul 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Jul 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. MX 2013007491

    GRANULATES COMPRISING ESLICARBAZEPINE ACETATE.

    BIAL PORTELA & CA SA [PT] · Granted Thu Aug 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jul 27 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8501957

    Benzimidazole compounds and their use as anticancer agents

    China Medical University · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8501804

    Bicyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8501182

    Monoclonal antibodies that react with the capsule of Bacillus anthracis

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8501184

    High affinity human antibodies to PCSK9

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8501247

    Pest control using natural pest control agent blends

    TYRATECH, INC. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8501446

    Azaindoles useful as inhibitors of JAK and other protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8501686

    Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8501776

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8501798

    Dual-acting antihypertensive agents

    Theravance, Inc. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8501920

    Nucleic acid sequences encoding peptides with utrophin spectrin-like repeats

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8501926

    Malaria vaccine

    The United States of America as represented by the Secretary of the Army · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8501953

    PKM2 modulators for use in the treatment of cancer

    Agios Pharmaceuticals, Inc. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8501964

    Serotonin reuptake inhibitors

    Theravance, Inc. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8501404

    Gnaq mutations in melanoma

    The Regents of the University of California · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8501959

    Cycloalkane[B]indole antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8501943

    Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor

    Almirall, S.A. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8501930

    Peptide-based in vivo siRNA delivery system

    Arrowhead Madison, Inc. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8501803

    Garcinia derivative, its preparing method and medicinal use

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8501899

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Serina Therapeutics, Inc. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8501912

    Filipil compositions and methods for treating cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8501905

    Synthetic cell platforms and methods of use thereof

    The Regents of the University of California · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8501783

    Conformationally restricted urea inhibitors of soluble epoxide hydrolase

    The Regents of the University of California · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8501750

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8501766

    Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8501746

    Organic compounds

    Xenon Pharmaceuticals Inc. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8501740

    Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors

    The Board of Regents of the University of Texas System · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8501727

    Short acting benzothiazepine calcium channel blockers and uses thereof

    Milestone Pharmaceuticals Inc. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2033?

1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.